We would like to welcome you to the 2026 Global XDC Innovation Conference. This convention has evolved as a platform to explore technologies shaping next-generation drug design toolkit, map the translational journey into new disease landscapes, and evaluate how a collaborative, globalized innovation ecosystem is essential to turning potential into reality for patients worldwide.
Antibody-Drug Conjugates (ADCs) has decisively moved from a "promising niche" to the center of modern oncology, redefining treatment standards, and patient outcomes. Not only is this the beginning of broadening of ADC Blueprint but also ignition of a revolution, giving rise to a new generation of novel bioconjugates: BsADCs, AOCs, Dual-Payload ADCs, RDCs, APCs, and beyond.
We stand at a historic inflection point. So, we are bringing scientists/entrepreneurs/leaders together at the 2026 Global XDC Innovation Conference which explores the two defining aspects shaping the future of medicine: Convergence - the fusion of diverse novel modalities to build smarter medicines; Innovation - the strategic pursuit of new therapeutic frontiers beyond established boundaries.
